Prices are updated after-hours


Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date

symbols : Pfe    save search

Pfizer Announces Topline Phase 2b Results of Oral GLP-1R Agonist, Danuglipron, in Adults with Obesity
Published: 2023-12-01 (Crawled : 22:00) - biospace.com/
PFE | $28.91 -5.12% 0.0% 100M twitter stocktwits trandingview |
Health Technology
| | O: -4.15% H: 0.0% C: 0.0%

obesity topline results
FDA Grants Priority Review for Supplemental Biologics License Application (sBLA) of PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
Published: 2023-11-30 (Crawled : 22:00) - prnewswire.com
PFE | $28.91 -5.12% 0.0% 100M twitter stocktwits trandingview |
Health Technology
| | O: -4.15% H: 0.0% C: 0.0%

padcev fda license review bladder cancer treatment application grants
Astellas' Fezolinetant Reduces Frequency and Severity of VMS Associated with Menopause in Women Considered Unsuitable for Hormone Therapy
Published: 2023-11-29 (Crawled : 00:00) - prnewswire.com
ALPMY | $12.28 0.99% -0.08% 190K twitter stocktwits trandingview |
Manufacturing
| | O: 0.66% H: 0.0% C: -0.16%
PFE | $28.91 -5.12% 0.0% 100M twitter stocktwits trandingview |
Health Technology
| | O: 1.71% H: 0.0% C: 0.0%

women therapy hormone
Arvinas and Pfizer Announce Updated Vepdegestrant (ARV-471) Data to be Presented at the 2023 San Antonio Breast Cancer Symposium
Published: 2023-11-28 (Crawled : 22:00) - globenewswire.com
PFE | $28.91 -5.12% 0.0% 100M twitter stocktwits trandingview |
Health Technology
| | O: -1.15% H: 0.0% C: 0.0%
ARVN | $23.6 7.42% 1.27% 820K twitter stocktwits trandingview |
Health Technology
| | O: 1.72% H: 4.07% C: 0.6%

arv-471 breast symposium cancer
Arvinas Announces Oversubscribed $350 Million Private Placement
Published: 2023-11-27 (Crawled : 12:00) - globenewswire.com
PFE | $28.91 -5.12% 0.0% 100M twitter stocktwits trandingview |
Health Technology
| | O: 0.81% H: 0.0% C: 0.0%
ARVN | $23.6 7.42% 1.27% 820K twitter stocktwits trandingview |
Health Technology
| | O: 2.8% H: 11.93% C: 7.54%


Global Synthetic Hormones Market Analysis and Forecast, 2023-2033: Focus on Product Type, Application, Route of Administration, End User, Region, and Competitive Landscape
Published: 2023-11-25 (Crawled : 00:20) - prnewswire.com
PFE | $28.91 -5.12% 0.0% 100M twitter stocktwits trandingview |
Health Technology
| Email alert Add to watchlist
LLY 2 d | $584.04 -1.18% 0.34% 3.6M twitter stocktwits trandingview |
Health Technology
| Email alert Add to watchlist
NVS | $98.13 0.24% -0.16% 1.2M twitter stocktwits trandingview |
Health Technology
| Email alert Add to watchlist
NVSEF | $97.95 1.48% 2.98% 100 twitter stocktwits trandingview |
Health Technology
| Email alert Add to watchlist

global market
Global Vaginitis Therapeutics Market Size Projected to Reach USD 7.20 Billion By 2032, With 8.1% CAGR Growth: Polaris Market Research
Published: 2023-11-23 (Crawled : 15:30) - prnewswire.com
PFE | $28.91 -5.12% 0.0% 100M twitter stocktwits trandingview |
Health Technology
| Email alert Add to watchlist
NVSEF | $97.95 1.48% 2.98% 100 twitter stocktwits trandingview |
Health Technology
| Email alert Add to watchlist
NVS | $98.13 0.24% -0.16% 1.2M twitter stocktwits trandingview |
Health Technology
| Email alert Add to watchlist

reach research global therapeutics market
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference - November 21, 2023
Published: 2023-11-21 (Crawled : 17:00) - biospace.com/
PFE | $28.91 -5.12% 0.0% 100M twitter stocktwits trandingview |
Health Technology
| | O: 0.13% H: 1.13% C: 0.93%

conference
Pfizer and Astellas' XTANDI® Approved by U.S. FDA in Earlier Prostate Cancer Treatment Setting
Published: 2023-11-17 (Crawled : 04:00) - prnewswire.com
PFE | $28.91 -5.12% 0.0% 100M twitter stocktwits trandingview |
Health Technology
| | O: -1.09% H: 0.0% C: 0.0%

xtandi fda approved cancer treatment
Oncology Drugs Market worth $520 billion by 2033 - Exclusive Report by We Market Research
Published: 2023-11-10 (Crawled : 15:00) - prnewswire.com
PFE | $28.91 -5.12% 0.0% 100M twitter stocktwits trandingview |
Health Technology
| | O: -4.83% H: 0.0% C: 0.0%
JNJ | $158.38 2.41% 0.0% 10M twitter stocktwits trandingview |
Health Technology
| | O: -1.24% H: 0.0% C: 0.0%
BMY P | $50.1 1.46% 0.26% 11M twitter stocktwits trandingview |
Health Technology
| | O: -3.68% H: 0.0% C: 0.0%
ABBV | $143.41 0.72% 0.18% 3.6M twitter stocktwits trandingview |
Health Technology
| | O: 0.44% H: 0.0% C: 0.0%
AZN | $64.79 0.31% 0.03% 3.6M twitter stocktwits trandingview |
Health Technology
| | O: -2.88% H: 0.0% C: 0.0%

report research market
Arvinas Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Published: 2023-11-07 (Crawled : 12:00) - globenewswire.com
PFE | $28.91 -5.12% 0.0% 100M twitter stocktwits trandingview |
Health Technology
| | O: -0.86% H: 0.98% C: 0.55%
ARVN | $23.6 7.42% 1.27% 820K twitter stocktwits trandingview |
Health Technology
| | O: -1.33% H: 4.2% C: 4.04%

update financial results
Valneva to Present and Hold Investor Meetings at the Jefferies London Healthcare Conference
Published: 2023-11-07 (Crawled : 06:00) - globenewswire.com
PFE | $28.91 -5.12% 0.0% 100M twitter stocktwits trandingview |
Health Technology
| | O: -0.86% H: 0.98% C: 0.55%

conference valneva
BioNTech Announces Third Quarter 2023 Financial Results and Corporate Update
Published: 2023-11-06 (Crawled : 12:00) - globenewswire.com
GNMSF | $314.475 -1.42% -0.25% 860 twitter stocktwits trandingview |
Health Technology
| | O: 4.19% H: 3.29% C: -1.11%
PFE | $28.91 -5.12% 0.0% 100M twitter stocktwits trandingview |
Health Technology
| | O: 1.55% H: 0.0% C: 0.0%
SNY | $46.72 -0.06% -0.06% 1.1M twitter stocktwits trandingview |
Health Technology
| | O: 0.21% H: 0.0% C: 0.0%
GMAB | $31.97 1.14% 1.11% 680K twitter stocktwits trandingview |
Health Technology
| | O: 0.93% H: 0.44% C: -1.37%
BNTX | $99.4 -1.01% -1.02% 760K twitter stocktwits trandingview |
Health Technology
| | O: 6.29% H: 3.18% C: -1.55%

update financial results
Pfizer Reports Third-Quarter 2023 Results
Published: 2023-10-31 (Crawled : 12:00) - biospace.com/
HLN | $8.58 0.23% 0.0% 4.7M twitter stocktwits trandingview |
n/a
| | O: 0.87% H: 0.0% C: 0.0%
PFE | $28.91 -5.12% 0.0% 100M twitter stocktwits trandingview |
Health Technology
| | O: 0.36% H: 0.0% C: 0.0%
BNTX | $99.4 -1.01% -1.02% 760K twitter stocktwits trandingview |
Health Technology
| | O: 1.59% H: 0.0% C: 0.0%
AZN | $64.79 0.31% 0.03% 3.6M twitter stocktwits trandingview |
Health Technology
| | O: 0.14% H: 0.0% C: 0.0%

results
Anti-inflammatory Therapeutics Market Size to Hit US$ 149.5 billion by 2031 | Exclusive Study by Transparency Market Research
Published: 2023-10-30 (Crawled : 09:00) - prnewswire.com
SNYNF | $94.0 1.34% 1.34% 860 twitter stocktwits trandingview |
Health Technology
| | O: 2.76% H: 0.0% C: 0.0%
PFE | $28.91 -5.12% 0.0% 100M twitter stocktwits trandingview |
Health Technology
| | O: -2.42% H: 0.0% C: 0.0%
NVS | $98.13 0.24% -0.16% 1.2M twitter stocktwits trandingview |
Health Technology
| | O: -0.15% H: 0.25% C: -0.07%
JNJ | $158.38 2.41% 0.0% 10M twitter stocktwits trandingview |
Health Technology
| | O: -1.39% H: 0.79% C: 0.64%
GSK | $36.57 1.61% -0.06% 2.5M twitter stocktwits trandingview |
Health Technology
| | O: 0.03% H: 0.44% C: -0.23%
ABBV | $143.41 0.72% 0.18% 3.6M twitter stocktwits trandingview |
Health Technology
| | O: 2.87% H: 0.0% C: 0.0%
SNY | $46.72 -0.06% -0.06% 1.1M twitter stocktwits trandingview |
Health Technology
| | O: -0.85% H: 0.0% C: 0.0%

research therapeutics study market
Everest Medicines Announces New Drug Application Approval by the Pharmaceutical Administration Bureau of Macau for Nefecon® for the Treatment of Primary IgA Nephropathy
Published: 2023-10-27 (Crawled : 06:00) - prnewswire.com
PFE | $28.91 -5.12% 0.0% 100M twitter stocktwits trandingview |
Health Technology
| | O: 1.57% H: 0.0% C: 0.0%

nefecon nephropathy drug approval treatment application
Everest Medicines Announces Poster Presentation at ASN Kidney Week on Nefecon® Chinese Patient Data and to Hold Conference Calls
Published: 2023-10-27 (Crawled : 01:00) - prnewswire.com
PFE | $28.91 -5.12% 0.0% 100M twitter stocktwits trandingview |
Health Technology
| | O: 1.57% H: 0.0% C: 0.0%
CALT | $17.9 3.17% -0.73% 3.9K twitter stocktwits trandingview |
Health Technology
| | O: 2.58% H: 0.08% C: -3.42%

nefecon conference kidney presentation chinese week
Pfizer and BioNTech Announce Positive Topline Data for mRNA-based Combination Vaccine Program Against Influenza and COVID-19
Published: 2023-10-26 (Crawled : 11:00) - globenewswire.com
PFE | $28.91 -5.12% 0.0% 100M twitter stocktwits trandingview |
Health Technology
| | O: 0.26% H: 0.0% C: 0.0%
SNY | $46.72 -0.06% -0.06% 1.1M twitter stocktwits trandingview |
Health Technology
| | O: 0.09% H: 0.0% C: 0.0%
BNTX | $99.4 -1.01% -1.02% 760K twitter stocktwits trandingview |
Health Technology
| | O: 1.1% H: 1.81% C: 0.47%

covid-19 vaccine positive influenza topline program
Rising R&D Investment and Government Support Fuel Expansion of Global Duchenne Muscular Dystrophy Drugs Market
Published: 2023-10-24 (Crawled : 23:00) - prnewswire.com
PFE | $28.91 -5.12% 0.0% 100M twitter stocktwits trandingview |
Health Technology
| | O: 0.1% H: 0.0% C: 0.0%
LLY 2 d | $584.04 -1.18% 0.34% 3.6M twitter stocktwits trandingview |
Health Technology
| | O: 2.75% H: 0.46% C: -1.76%
BMY P | $50.1 1.46% 0.26% 11M twitter stocktwits trandingview |
Health Technology
| | O: -0.34% H: 1.34% C: 1.05%
PTCT | $23.99 4.21% -0.21% 1.1M twitter stocktwits trandingview |
Health Technology
| | O: -1.34% H: 2.23% C: 1.62%
LXRX | $1.15 8.49% 0.87% 2.1M twitter stocktwits trandingview |
Health Technology
| | O: -1.68% H: 0.85% C: -2.99%

expansion global duchenne market
Novartis Kisqali® NATALEE analysis reinforces consistent reduction in risk of recurrence across key subgroups of patients with early breast cancer
Published: 2023-10-20 (Crawled : 10:00) - globenewswire.com
PFE | $28.91 -5.12% 0.0% 100M twitter stocktwits trandingview |
Health Technology
| | O: -0.94% H: 0.0% C: 0.0%
NVS | $98.13 0.24% -0.16% 1.2M twitter stocktwits trandingview |
Health Technology
| | O: -0.39% H: 0.0% C: 0.0%

kisqali breast cancer risk novartis
Gainers vs Losers
77% 23%

Top 10 Gainers
ID 4 | $0.077 -9.41% 25.97% 420K twitter stocktwits trandingview |
Finance

BKKT 4 | $1.88 25.33% 14.89% 4.8M twitter stocktwits trandingview |

MGLD | $1.03 7.77% 14K twitter stocktwits trandingview |
Manufacturing

CZOO | $0.4316 -6.52% 6.7% 65K twitter stocktwits trandingview |

SATX | $0.4226 -1.72% 6.48% 29K twitter stocktwits trandingview |
n/a

CCJ | $45.4 -1.13% 4.6% 3.9M twitter stocktwits trandingview |
Non-Energy Minerals

AUMN | $0.562 0.34% 4.5% 360K twitter stocktwits trandingview |
Non-Energy Minerals

JBL | $116.91 1.38% 4.3% 2M twitter stocktwits trandingview |
Electronic Technology

SAIC 4 | $119.92 2.14% 4.24% 460K twitter stocktwits trandingview |
Technology Services

CULP 4 | $5.06 -0.59% 3.95% 29K twitter stocktwits trandingview |
Process Industries


Your saved searches
Save your searches and get alerts when important news are released.